Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAVO412 in advanced solid tumors
NCT06761651Phase 1Recruiting
- Sponsor
- Tavotek Biotherapeutics
- Start
- Dec 2023
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Trispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of tavo412 in solid tumor, gastric cancer (GC), non-small cell lung cancer (NSCLC) and 1 more (7 cohorts), sponsored by Tavotek Biotherapeutics. Primary endpoint: Safety and Tolerability of TAVO412 according to Adverse Events and Number of Participants With Dose Limiting Toxicity (DLT) at 12 months. Started Dec 2023; status: recruiting.
02
Drugs
tavo412
03
Conditions
solid tumorgastric cancer (GC)non-small cell lung cancer (NSCLC)hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT06761651.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06761651.